Compare iShares MSCI South Korea ETF (EWY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $175.57, while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWY | HRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $1.49 |
52-Week Low | $71.22 | $0.32 |
Market Cap | — | $61.47M |
Enterprise Value | — | $168.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $174.49, up 6.97% in 24 hours, with a neutral technical signal overall. Recent news highlights South Korea's semiconductor sector volatility and government support initiatives, including a $3.52 billion fund for chip materials. The ETF's performance is tied to heavyweights like Samsung and SK Hynix, which have faced sharp declines amid AI-driven market swings.
Outlook remains cautious due to sector concentration risks and foreign capital outflows, but long-term potential exists if semiconductor demand stabilizes. Investors face volatility from leveraged ETF speculation curbs and global tech sentiment shifts, requiring careful risk assessment amid mixed analyst views.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
